Bicycle Therapeutics plc
BCYC
$4.72
$0.020.43%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 105.77% | -23.20% | -51.28% | -38.18% | 30.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 105.77% | -23.20% | -51.28% | -38.18% | 30.76% |
| Cost of Revenue | 38.54% | 37.14% | 36.70% | 19.78% | 6.47% |
| Gross Profit | -20.48% | -53.89% | -65.07% | -40.25% | -1.41% |
| SG&A Expenses | 9.29% | 32.82% | 39.49% | 32.21% | 28.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.26% | 35.96% | 37.46% | 23.26% | 12.50% |
| Operating Income | -16.33% | -47.07% | -56.61% | -37.47% | -9.91% |
| Income Before Tax | -25.90% | -49.05% | -52.26% | -25.41% | 3.02% |
| Income Tax Expenses | 103.19% | 34.73% | -348.11% | -418.96% | -427.04% |
| Earnings from Continuing Operations | -29.54% | -50.75% | -46.56% | -20.85% | 6.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.54% | -50.75% | -46.56% | -20.85% | 6.44% |
| EBIT | -16.33% | -47.07% | -56.61% | -37.47% | -9.91% |
| EBITDA | -17.28% | -49.02% | -58.42% | -38.62% | -9.92% |
| EPS Basic | -9.88% | -10.30% | 7.95% | 29.70% | 43.93% |
| Normalized Basic EPS | -3.85% | -11.58% | 3.31% | 26.47% | 41.54% |
| EPS Diluted | -9.88% | -10.30% | 7.95% | 29.70% | 43.93% |
| Normalized Diluted EPS | -3.85% | -11.58% | 3.31% | 26.47% | 41.54% |
| Average Basic Shares Outstanding | 19.14% | 34.40% | 56.61% | 67.52% | 63.58% |
| Average Diluted Shares Outstanding | 19.14% | 34.40% | 56.61% | 67.52% | 63.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |